Pacira BioSciences, Inc.PCRXNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank85
3Y CAGR+34.6%
5Y CAGR+83.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+34.6%/yr
vs +26.6%/yr prior
5Y CAGR
+83.2%/yr
Recent deceleration
Acceleration
+8.0pp
Accelerating
Percentile
P85
Within normal range
vs 5Y Ago
20.7x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 10.69% |
| Q3 2025 | 3.63% |
| Q2 2025 | 2.08% |
| Q1 2025 | 9.00% |
| Q4 2024 | 7.10% |
| Q3 2024 | 9.11% |
| Q2 2024 | -5.41% |
| Q1 2024 | 9.46% |
| Q4 2023 | -3.16% |
| Q3 2023 | 4.78% |
| Q2 2023 | -8.46% |
| Q1 2023 | 10.74% |
| Q4 2022 | 4.38% |
| Q3 2022 | -5.72% |
| Q2 2022 | 1.16% |
| Q1 2022 | 25.50% |
| Q4 2021 | 6.99% |
| Q3 2021 | -5.82% |
| Q2 2021 | 4.72% |
| Q1 2021 | -8.16% |
| Q4 2020 | 0.52% |
| Q3 2020 | 21.27% |
| Q2 2020 | -3.21% |
| Q1 2020 | -17.42% |
| Q4 2019 | 8.17% |
| Q3 2019 | 2.04% |
| Q2 2019 | 1.25% |
| Q1 2019 | 8.67% |
| Q4 2018 | 1.06% |
| Q3 2018 | -0.16% |
| Q2 2018 | 0.13% |
| Q1 2018 | 12.80% |
| Q4 2017 | -3.61% |
| Q3 2017 | 2.76% |
| Q2 2017 | -6.10% |
| Q1 2017 | 21.48% |
| Q4 2016 | -4.52% |
| Q3 2016 | -16.84% |
| Q2 2016 | 15.05% |
| Q1 2016 | 1.08% |